Overview

A Study of Trabectedin in Patients With Advanced Ovarian Cancer

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with advanced ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborator:
PharmaMar
Treatments:
Antineoplastic Agents, Alkylating
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Trabectedin